Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
The worldwide hepatitis C (HCV) market is forecast to grow from $4.7 billion in 2012 to $17.7 billion in 2017. The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and tolerable pipeline agents.
Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that will shape the future HCV market.
Therapy Trends Consensus Outlook: HIV includes the following comprehensive resources:
An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
Updated reports and data analysis files delivered to your inbox after each significant market event.
Key Benefits
Therapy Trends Consensus Outlook: Hepatitis C provides:
The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
Methodology
For each Therapy Trends report, FirstWord analysts produce a data analysis module-a Consensus Outlook-which provides annual historical and forecast product-level sales data. Historical sales data is derived from company information, while the five-year (2012-2017) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.
Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections–produced either internally or by other third parties–can be assessed.
Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.
Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.
Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that will shape the future HCV market.
Therapy Trends Consensus Outlook: HIV includes the following comprehensive resources:
An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
Updated reports and data analysis files delivered to your inbox after each significant market event.
Key Benefits
Therapy Trends Consensus Outlook: Hepatitis C provides:
- Evaluate future sales forecasts and predicted market growth
- Map your market parameters and chart commercial prospects
- Assess market share by company and product
- Tailor your strategic and investment focus based on the competition
- Set proactive launch and branding strategies
- Keep up with event-driven market data updates
The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
- Historical HCV sales from 2007–2012
- Forecast HCV sales from 2013-2017
- Key competitors and drug developers
- Predicted product positioning
- Current and late-stage pipeline drugs
- Future event mapping to forecast data points
- Comparative clinical trial results
- Market size
- Product sales
- Company forecasts
- Company, brand, and drug class
- Mechanism of action Future events
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
Methodology
For each Therapy Trends report, FirstWord analysts produce a data analysis module-a Consensus Outlook-which provides annual historical and forecast product-level sales data. Historical sales data is derived from company information, while the five-year (2012-2017) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.
Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections–produced either internally or by other third parties–can be assessed.
Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.
Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.
Market Overview
Hepatitis C Marketplace
Key Hepatitis C Developers
Hepatitis C Class Dynamics
Product Forecasts
Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast
Victrelis (boceprevir; Merck) forecast
PegaSys (pegylated interferon-alpha; Roche) forecast
PegIntron (pegylated interferon-alpha; Merck) forecast
Sofosbuvir (GS-7977, Gilead) forecast
Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast
Bristol-Myers Squibb franchise (daclastasvir/asunaprevir) forecast
Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast
MK-5172 (Merck) forecast
Vaniprevir (MK-7009; Merck) forecast
Simeprevir (TMC435; Medivir/Tibotec) forecast
VX-222 (Vertex) forecast
Hepatitis C Marketplace
Key Hepatitis C Developers
Hepatitis C Class Dynamics
Product Forecasts
Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast
Victrelis (boceprevir; Merck) forecast
PegaSys (pegylated interferon-alpha; Roche) forecast
PegIntron (pegylated interferon-alpha; Merck) forecast
Sofosbuvir (GS-7977, Gilead) forecast
Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast
Bristol-Myers Squibb franchise (daclastasvir/asunaprevir) forecast
Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast
MK-5172 (Merck) forecast
Vaniprevir (MK-7009; Merck) forecast
Simeprevir (TMC435; Medivir/Tibotec) forecast
VX-222 (Vertex) forecast
